Johnson & Johnson (JNJ) Cash & Equivalents (2009 - 2026)

Johnson & Johnson's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $21.7 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 43.63% year-over-year to $21.7 billion; the TTM figure through Mar 2026 stood at $21.7 billion (down 43.63% YoY), while the FY2025 annual figure was $19.7 billion, down 18.24% from the prior year.
• Cash & Equivalents came in at $21.7 billion for Q1 2026 at Johnson & Johnson, up from $19.7 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $38.5 billion in Q1 2025 to a low of $10.5 billion in Q2 2022.
• A 5-year average of $19.6 billion and a median of $19.7 billion in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 92.87% in 2023 and sank 43.63% in 2026, its largest moves.
• Johnson & Johnson's Cash & Equivalents stood at $11.4 billion in 2022, then jumped by 92.51% to $21.9 billion in 2023, then rose by 10.27% to $24.1 billion in 2024, then retreated by 18.24% to $19.7 billion in 2025, then rose by 10.04% to $21.7 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $21.7 billion, $19.7 billion, and $18.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison